Please note that this meeting will take place as an in-person event in Denver and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the Registration page for details. 

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress. 

*-Short talk from proffered abstract

Wednesday, March 15

Welcome and Opening Keynote Lecture

Thursday, March 16

Plenary Session 1: Mechanisms of Disease Progression 
Plenary Session 2: Genomic Heterogeneity
Plenary Session 3: Epigenomic Mechanisms
Lightning Lectures 1

Friday, March 17

Plenary Session 4: Modelling Prostate Cancer
Plenary Session 5: Lineage Plasticity and Treatment Resistance
Plenary Session 6: The Tumor Microenvironment and Immunotherapy 
Lightning Lectures 2

saturday, March 18

Plenary Session 7: Recent Advances in Detection and Diagnosis
Plenary Session 8: The Next Generation of Targeting Prostate Cancer

Wednesday, March 15

WELCOME AND Opening KEYNOTE LECTURE
5:30-6:30 P.M.

Welcoming Remarks 
Felix Y. Feng, University of California, San Francisco, California 

Introduction of the Keynote Speaker 
Cory Abate-Shen, Columbia University Irving Medical Center, New York, New York 

Prostate cancer genetics and tumor immunity 
Ronald A. DePinho, UT MD Anderson Cancer Center, Houston, Texas 

OPENING RECEPTION
6:30-8 P.M.

Thursday, March 16

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 1: Mechanisms of Disease Progression 
SESSION CHAIRS: Andrew S. Goldstein, University of California, Los Angeles, Los Angeles, California and Marcus Ruscetti, University of Massachusetts Chan Medical School, Worcester, Massachusetts 
8-10 A.M.

Genomic and epigenomic regulation during prostate cancer progression
Jindan Yu, Robert H. Lurie Comp. Cancer Ctr. of Northwestern Univ., Chicago, Illinois 

An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and AR therapy resistance* 
Ping Mu, UT Southwestern Medical Center, Dallas, Texas 

Evolution of AR gene structure during prostate cancer progression 
Scott M. Dehm, Masonic Cancer Center, Minneapolis, Minnesota 

Loss of protein phosphatase PP2A activity drive AR addiction in prostate cancer* 
Irfan A. Asangani, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 

Metabolic mechanisms of prostate cancer progression that feed nuclear receptors 
Nima Sharifi, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 

BREAK
10-10:30 A.M.

Plenary Session 2: Genomic Heterogeneity 
SESSION CHAIR: Anne E. Cress, University of Arizona Cancer Center, Tucson, Arizona and Adam G. Sowalsky, National Cancer Institute, Bethesda, Maryland 
10:30 A.M.–12:30 P.M.

The genetic underpinnings of prostate cancer genomic heterogeneity
Francesca Demichelis, University of Trento, Trentino, Italy 

Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer 
Alexander W. Wyatt, University of British Columbia, Vancouver, British Columbia, Canada 

Convergent evolution in DNA repair-deficient mCRPC in response to targeted therapy*
David A. Quigley, University of California San Francisco, San Francisco, California 

Science of prostate cancer care and survivorship in black men: Structural, social and biological determinants 
Folakemi T. Odedina, Mayo Clinic Florida, Jacksonville, Florida 

Integrative analysis of the genomic, transcriptomic, and chromatin landscape of PCa in Black men identifies actionable therapeutic vulnerabilities
Salma Kaochar, Baylor College of Medicine, Houston, Texas  

LUNCH ON OWN
12:45-2:30 P.M.

Plenary Session 3: Epigenomic Mechanisms 
SESSION CHAIR: Jelani Zarif, Johns Hopkins, Baltimore, Maryland and Amina Zoubeidi, University of British Columbia, Vancouver, BC, Canada 
2:30-4:30 P.M.

Interrogating the three dimensional genome architecture in metastatic prostate cancer 
Felix Y. Feng, University of California San Francisco, San Francisco, California 

Exploring the role of ASCL1 in neuroendocrine prostate cancer* 
Kathia E. Rodarte, UT Southwestern Medical Center, Dallas, Texas 

Prostate cancer transcriptomic regulation by germline risk alleles, somatic mutations and 3D-genomic architecture 
Ram S. Mani, UT Southwestern Medical Center, Dallas, Texas 

Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3’ untranslated region mutations* 
Samantha L. Schuster, Fred Hutchinson Cancer Center, Seattle, Washington 

Prostate stromal microenvironment: A scRNASeq map of mice and men 
Massimo Loda, Weill Cornell Medicine, New York, New York 

Lightning Lectures 1
Session Chairs: Cory Abate-Shen, Columbia University Irving Medical Center, New York, New York, Felix Y. Feng, University of California, San Francisco, California, and Scott A. Tomlins, University of Michigan Medical School and Strata Oncology, Ann Arbor, Michigan 
4:30-5 P.M.

NSD2 is a requisite and targetable subunit of the AR/FOXA1 neo-enhanceosome complex in prostate cancer cells 
Abhijit Parolia, University of Michigan, Ann Arbor, Michigan 

Alternative promoter usage is linked to transcriptional and epigenetic alterations during prostate cancer progression 
Meng Zhang, University of California, San Francisco, San Francisco, California 

Differential alternative RNA splicing and transcription events between Black and White prostate cancer patients involve genes promoting cancer aggressiveness and associate with patient survival 
Muthana Al Abo, Duke University, Durham, North Carolina 

Minor intron splicing is critical for survival of lethal prostate cancer 
Anke Augspach, University of Bern-DBMR, Bern, Switzerland 

Enzalutamide resistance is driven by adaptations that enhance AR splice variant and FOXA1 activities 
Betul Ersoy-Fazlioglu, Harvard University Beth Israel Deaconess Medical Center, Boston, Massachussetts 

Distinct activity of androgen receptor splice variants in promoting prostate cancer metastasis 
Maryam Labaf, University of Massachusetts Boston, Boston, Massachussetts 

BMX inhibition reverses HSD3B1-driven resistance in prostate cancer 
Xiuxiu Li, Cleveland Clinic, Shaker Heights, Ohio 

Cellular cartography reveals transcriptional specificity and spatial organization of diverse luminal epithelial cells in the murine prostate 
Hanbyul Cho, University of Michigan, Ann Arbor, Michigan 

Human Prostate-on-Chip models to define stromal and epithelial interactions in normal and cancerous prostate 
Cindy K. Miranti, University of Arizona Cancer Center, University of Arizona, Tucson, Arizona 

Identifying and targeting the genetic determinants of immune suppression and immunotherapy failure in prostate cancer. 
Katherine C. Murphy, UMass Chan Medical School, Worcester, Massachusetts 

POSTER SESSION A/RECEPTION
5-7:30 P.M.

Friday, March 17

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 4: Modeling Prostate Cancer 
SESSION CHAIrs: Di Zhao, UT MD Anderson Cancer Center, Houston, Texas 
8-10 A.M.

Modeling prostate cancer metastasis in genetically engineered mouse models
Cory Abate-Shen, Columbia University Irving Medical Center, New York, New York 

PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer* 
Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia 

Using patient derived models to define epigenetic subtypes of castration-resistant prostate cancer 
Yu Chen, Memorial Sloan Kettering Cancer Center, New York, New York 

ERG-driven luminal prostate cancers emerge from Ck5+/Nkx3.1+ basal cells* 
Weiran Feng, Memorial Sloan Kettering Cancer Center, New York, New York 

Drug sensitivity of multifocal primary prostate cancer
Marianna Kruithof-de Julio, University of Bern, Bern, Switzerland 

BREAK
10-10:30 A.M.

Plenary Session 5: Lineage Plasticity and Treatment Resistance 
SESSION CHAIRs: Himisha Beltran, Dana-Farber Cancer Institute, Boston, Massachusetts and Lawrence True, University of Washington, Seattle, Washington 
10:30 A.M.-12:30 P.M.

Lineage fidelity and plasticity in prostate development and cancer 
Michael M. Shen, Columbia University Irving Medical Center, New York, New York 

Molecular determinants of prostate cancer lineage plasticity* 
David W. Goodrich, Roswell Park Comprehensive Cancer Center, Buffalo, New York 

Epigenetic crosstalk associated with prostate cancer lineage plasticity
David S. Rickman, Weill Cornell Medicine, New York, New York 

Basal cell lineage plasticity in prostate homeostasis, repair and tumor initiation* 
Dong Gao, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China (Mainland) 

Anticipating, tracking, and targeting new prostate cancer lineages driven by treatment pressures
Peter S. Nelson, Fred Hutchinson Cancer Center, Seattle, Washington 

Lunch Break (Lunch on your own)
12:30-2:30 P.M.

Plenary Session 6: The Tumor Microenvironment and Immunotherapy 
SESSION CHAIR: Cindy K. Miranti, University of Arizona Cancer Center, University of Arizona, Tucson, Arizona and Ayesha Shafi, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland  
2:30-4:30 P.M.

Exploiting androgen blockade to improve anti-tumor immunity 
Amy Moran, OHSU, Portland, Oregon 

First-in-class TRPV6 inhibitors for the treatment of prostate cancer* 
Kimberley Beaumont, Uniquest, St Lucia, QLD, Australia 

Tumor microenvironment modulation is critical for cellular immunotherapy efficacy 
Tanya Dorff, City of Hope Comprehensive Cancer Ctr., Duarte, California 

The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: a clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer* 
Marcin P. Cieslik, University of Michigan, Ann Arbor, Michigan 

Senescence in cancer and myeloid cells control prostate cancer progression
Andrea Alimonti, IOR – Institute of Oncology Research, Bellinzona, Switzerland 

Lightning Lectures 2
Session Chairs: Cory Abate-Shen, Columbia University Irving Medical Center, New York, New York, Felix Y. Feng, University of California, San Francisco, California, and Scott A. Tomlins, University of Michigan Medical School and Strata Oncology, Ann Arbor, Michigan 
4:30-5 P.M.

Lactate metabolism regulates chromatin accessibility and prostate luminal differentiation 
Andrew S. Goldstein, University of California, Los Angeles, Los Angeles, California 

Lineage-specific PRC2 targets and response to EZH2 inhibition in neuroendocrine prostate cancer 
Varadha Balaji Venkadakrishnan, Dana-Farber Cancer Institute, Boston, Massachussetts 

Characterization of DNA repair defects in CDK12 mutant prostate cancer and the identification of differential vulnerabilities 
Sander Frank, Fred Hutchinson Cancer Center, Seattle, Washington 

Genome-wide CRISPR screens identify PTGES3 as a druggable AR modulator 
Haolong Li, University of California, San Francisco, San Francisco, California 

Targeting CBP/p300 and its downstream transcriptional machinery in advanced PCa 
Ayesha A. Shafi, Center for Prostate Disease Research, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland 

Elevated mitochondrial reactive oxygen species dysregulate the tumor microenvironment in prostate cancer of African American Men 
Asmaa El-Kenawi, Moffitt Cancer Center, Tampa, Florida 

Leveraging therapy-induced senescence for prostate cancer immunotherapy 
Marcus Ruscetti, University of Massachusetts Chan Medical School, Worcester, Massachusetts 

Poster Session B (with light refreshments)
5-7:30 p.m.

Saturday, march 18

BREAKFAST
7-8 A.M.

Plenary Session 7: Recent Advances in Detection and Diagnosis 
SESSION CHAIR: Lisa M. Butler, University of Adelaide, Adelaide, Australia and Lisa F. Newcomb, Fred Hutchinson Cancer Center, Seattle, Washington 
8-10 A.M.

From a single to million cell view of prostate cancer 
Franklin W. Huang, University of California, San Francisco, California

Ultra-sensitive detection of circulating tumour DNA enriches for patients with higher risk disease in clinically localised prostate cancer* 
Bernard J. Pope, The University of Melbourne, Melbourne, VIC, Australia  

Risk stratification of localized prostate cancer: NRG oncology digital pathology initiatives to improve precision medicine radiation management 
Phuoc T. Tran, University of Maryland, Baltimore, Baltimore, Maryland 

Unlocking the proteome of metastatic prostate cancer circulating tumor cells* 
Justin M. Drake, University of Minnesota, Minneapolis, Minnesota 

Prostate cancer diagnosis: Where we are and where are we going? 
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, Michigan 

BREAK
10-10:30 A.M.

Plenary Session 8: The Next Generation of Targeting Prostate Cancer 
SESSION CHAIR: Scott A. Tomlins, University of Michigan Medical School and Strata Oncology, Ann Arbor, Michigan
10:30-12:30 P.M.

Investigating myeloid cells and epigenetic pathways that drive resistance to immune checkpoint therapy 
Padmanee Sharma, UT MD Anderson Cancer Center, Houston, Texas 

Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer* 
Li Jia, Brigham and Women’s Hospital, Boston, Massachusetts

Targeting epigenetic regulators of oncogenic transcription factors 
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Michigan 

Inhibition of androgen receptor signaling in castrate resistant prostate cancer in association with inhibition of glycolysis by targeting hexokinase 2 activity with pyrrolopyrimidine-based small molecules* 
Takuma Uo, University of Washington, Seattle, Washington 

Novel therapeutic strategies for treating prostate cancer 
Johann S. de Bono, The Institute of Cancer Research, London, London, United Kingdom 

 

CLOSING REMARKS
12:30 P.M.

Scott A. Tomlins, University of Michigan Medical School and Strata Oncology, Ann Arbor, Michigan